Tuesday, January 27, 2015
BioCryst Earns Special FDA designation
BioCryst Pharmaceuticals received Fast Track designation for its experimental treatment for hereditary angioedema.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment